[144] Cellebrite DI Ltd. Warrants SEC Filing

Rhea-AI Filing Summary

Cellebrite DI Ltd. (CLBTW) Form 144 filing documents a proposed sale of 2,814 common shares by an insider through Morgan Stanley Smith Barney LLC on 09/08/2025 with an aggregate market value of $46,740.54. The filing shows the insider acquired 1,087 shares on 09/08/2025 by exercising stock options and 1,727 shares on 08/06/2025 via restricted stock units. The issuer has 244,469,106 shares outstanding per the form. The filer also reported a prior 10b5-1 sale of 2,814 shares on 08/20/2025 that generated gross proceeds of $43,954.68. The filer attests they are not aware of undisclosed material adverse information.

Positive

• Clear compliance with Rule 144 reporting requirements including broker, acquisition details, and attestation
• Transaction size is small relative to total shares outstanding (2,814 vs 244,469,106), indicating low market impact
• Compensation-based origin of shares (stock option exercise and RSU vesting) signals routine insider liquidity

Negative

• Recent sales noted include a prior 10b5-1 sale of the same quantity on 08/20/2025, which may indicate ongoing disposals
• Aggregate market value disclosed ($46,740.54) is modest but shows insider is selling shares shortly after acquisition dates

Insights

Securities Analyst

TL;DR: Insider plans to sell a small block of stock acquired mostly through compensation; transaction size is immaterial to market cap.

The filing details a proposed disposition of 2,814 common shares valued at $46,740.54 to be brokered by Morgan Stanley Smith Barney LLC on 09/08/2025. Acquisition dates indicate compensation-related origins: option exercise (1,087 shares) and RSU vesting (1,727 shares). With 244,469,106 shares outstanding, this sale represents a negligible fraction of outstanding equity. The filing also discloses a prior 10b5-1 sale on 08/20/2025 producing $43,954.68, suggesting these are scheduled or plan-driven dispositions rather than ad hoc large divestitures.

Corporate Governance Expert

TL;DR: Disclosure follows Rule 144 and references a 10b5-1 sale; attestation about material information is included.

The notice complies with Rule 144 reporting requirements and names the executing broker. It documents the nature of acquisition (exercise and RSUs) and payment methods (cash for exercised shares). The signer affirms no undisclosed material adverse information and references a trading plan when applicable. There are no indications of regulatory issues or unusually large insider liquidation in the filing itself.

09/08/2025 - 04:27 PM

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	2814	46740.54	244469106	09/08/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/08/2025	Exercise of Stock Options	Issuer			1087	09/08/2025	Cash
Common	08/06/2025	Restricted Stock Units	Issuer			1727	08/06/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for AYALA BERLER SHAPIRA 94 Shlomo Shmelzer Road Petah Tikva L3 4970602	COMMON	08/20/2025	2814	43954.68

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the CLBTW Form 144 filed on 09/08/2025 disclose?

The form discloses a proposed sale of 2,814 common shares via Morgan Stanley Smith Barney LLC on 09/08/2025 with aggregate market value of $46,740.54.

How were the shares being sold by the insider acquired?

The filing shows 1,087 shares were acquired on 09/08/2025 by exercising stock options and 1,727 shares vested as restricted stock units on 08/06/2025.

Does the filing indicate any undisclosed material information about Cellebrite DI Ltd. (CLBTW)?

The filer attests they do not know any material adverse information about the issuer that has not been publicly disclosed.

Were there any recent related sales by the same person?

Yes. The filing reports a prior 10b5-1 sale of 2,814 shares on 08/20/2025 for gross proceeds of $43,954.68.

Who is the broker named in the Form 144?

The executing broker listed is Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.